Search research articles
Contact Us
Filters
Showing results (691-700 of 829) with videos related to
Page
of 83
Sort By:
Endocrine-Related Cancer
|
September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.
Cancer Medicine
|
May 17, 2018
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
Haider H Samawi, Hao-Wen Sim, Kelvin K Chan, et al.
Diseases of the Colon and Rectum
|
January 24, 2022
Impact of Definitive Chemoradiation on Quality-of-Life Changes for Patients With Anal Cancer: Long-term Results of a Prospective Study
Ali Hosni, Jolie Ringash, Kathy Han, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Clinical Genitourinary Cancer
|
October 21, 2018
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies
Nils Kroeger, Haoran Li, Guillermo De Velasco, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial
R C Grant, K Duan, R Jackson, et al.
Journal of Medical Microbiology
|
October 1, 2021
2-Alkyl-4-quinolone quorum sensing molecules are biomarkers for culture-independent <i>Pseudomonas aeruginosa</i> burden in adults with cystic fibrosis
Nur Masirah M Zain, Karmel Webb, Iain Stewart, et al.
Transplantation
|
November 12, 2024
Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Christian T J Magyar, Sheron Perera, Luckshi Rajendran, et al.
Journal of Medicinal Chemistry
|
August 22, 2003
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition
Yong-Jin Wu, Carl D Davis, Steven Dworetzky, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 31, 2004
(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons
Yong-Jin Wu, Christopher G Boissard, Jie Chen, et al.
Page
of 83
Search research articles
Search
Showing results (691-700 of 829) with videos related to
Sort By:
Page
of 83
Endocrine-Related Cancer
|
September 13, 2023
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, et al.
Cancer Medicine
|
May 17, 2018
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
Haider H Samawi, Hao-Wen Sim, Kelvin K Chan, et al.
Diseases of the Colon and Rectum
|
January 24, 2022
Impact of Definitive Chemoradiation on Quality-of-Life Changes for Patients With Anal Cancer: Long-term Results of a Prospective Study
Ali Hosni, Jolie Ringash, Kathy Han, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Viktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.
Clinical Genitourinary Cancer
|
October 21, 2018
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies
Nils Kroeger, Haoran Li, Guillermo De Velasco, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial
R C Grant, K Duan, R Jackson, et al.
Journal of Medical Microbiology
|
October 1, 2021
2-Alkyl-4-quinolone quorum sensing molecules are biomarkers for culture-independent <i>Pseudomonas aeruginosa</i> burden in adults with cystic fibrosis
Nur Masirah M Zain, Karmel Webb, Iain Stewart, et al.
Transplantation
|
November 12, 2024
Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Christian T J Magyar, Sheron Perera, Luckshi Rajendran, et al.
Journal of Medicinal Chemistry
|
August 22, 2003
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition
Yong-Jin Wu, Carl D Davis, Steven Dworetzky, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 31, 2004
(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons
Yong-Jin Wu, Christopher G Boissard, Jie Chen, et al.
Page
of 83